Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

IVMED 85

Small molecule

IiVeena Delivery Systems, Inc.

IVMED 85 is one of 22 small molecule programs targeting Myopia. It is currently in development.

1

Indications

1

Total Trials

1

Active Trials

21

Competitors

Pipeline

Status by Indication[3][1]

Indication

MyopiaActive, not recruiting

MyopiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

58 competitors in Myopia

#DrugCompanyPhaseTrials

Atropen

FFresenius Kabi Oncology Ltd.

Alphagan

Isopto Carpine

Mitosol

UUroGen Pharma Ltd.

Oxylone

Lucentis

Lotemax

Mydriacyl

Avastin

BBio-Thera Solutions

Carboxymethylcellulose

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Not yet recruiting

Myopia

NCT05761795

Clinical

Trials by Indication[1]

Myopia1 trial

Efficacy of IVMED-85 on Pediatric Myopia

Not yet recruiting·IiVeena Delivery Systems, Inc.·Phase 1/2·NCT05761795·216 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IVMED 85. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IVMED 85 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IVMED 85. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — iVeena Delivery Systems, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: IiVeena Delivery Systems, Inc.

Related News